Co-CaReD
Financiado
In-cell Redox Catalysis by Co(III) Metallodrugs as New Tools for Cancer Treatments
The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more eff...
The search of new therapies for cancer is a primary EU mission. In-cell redox catalysis promoted by organometallic complexes of precious metals as Ru(II), Os(II), Rh(III) and Ir(III) is a novel promising concept to access more efficient, safer, and less invasive medicines.
Co-CaReD aims to design new in-cell catalytic systems based on half-sandwich Co(III) complexes. Cobalt combines effective catalytic performances for biomedical applications and high catalytic versatility. Moreover, it is a cheap, sustainable, and biocompatible metal whose peculiar chemical properties can access unique reactivity pathways. The project will focus on the development of new synthetic catalysts, on their applications in redox reactions of therapeutic interest, involving known examples and unprecedent cases of study, and on the unveiling of their biological mechanism of action in cancer cells.
Co-CaReD will be implemented in a vibrant and stimulating research environment at IMDEA Nanociencia, in Dr. Ana Pizarro research group. The project will benefit of the complementary expertise of the ER in organometallic chemistry and redox catalysis and of the supervisor in studying the intracellular reactivity at the molecular level of metal-based drugs. An intense training plan is designed to equip the researcher with the necessary skills to study the biological activity of the Co(III) catalysts – including single-cell studies – and to design proof-of-concept experiments that confirm the occurrence of a metal-based catalytic reactivity inside the human cells.
The main goal of Co-CaReD is to generate novel redox catalytic systems based on more biocompatible, less toxic, and cheaper cobalt drug candidates, as complementary tools to noble metal complexes.
ver más
Duración del proyecto: 37 meses
Fecha Inicio: 2023-06-28
Fecha Fin: 2026-08-27
Fecha Fin: 2026-08-27
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-28
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
FUNDACION IMDEA NANOCIENCIA
No se ha especificado una descripción o un objeto social para esta compañía.
